Advertisement

Topics

FDA Approves Enzalutamide for Nonmetastatic Prostate Cancer

13:56 EDT 13 Jul 2018 | Medscape

The oral therapy becomes the second androgen receptor-targeting therapy to be approved for use in this earlier disease setting.
FDA Approvals

Original Article: FDA Approves Enzalutamide for Nonmetastatic Prostate Cancer

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Enzalutamide for Nonmetastatic Prostate Cancer"

Advertisement
Quick Search
Advertisement
Advertisement